Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This study evaluates gender-based differences in hypoglycaemia symptoms and frequency among people with type 1 and insulin-treated type 2 diabetes using continuous glucose monitoring in real-world settings.
Elevated parathyroid hormone at the high-normal range independently predicts greater cardiovascular and all-cause mortality, with marked sex and age disparities in a large middle-aged Brazilian cohort.
A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
Thyroid hormone signaling may influence ADPKD progression, with preclinical cyst suppression and patient biomarker associations suggesting prognostic and therapeutic potential.
Time-restricted eating performed similarly to individualized dietetic guidance for short-term HbA1c change in adults at risk of type 2 diabetes, but non-inferiority was not confirmed at 12 months. Benefits were small, and adverse events wer
A Danish registry study found no overall increase in selected cancers after gestational diabetes, but did observe a small absolute and relative increase in kidney cancer risk.
A large real-world study found that public implementation of intermittently scanned continuous glucose monitoring in insulin-treated type 2 diabetes was linked to better HbA1c, fewer acute diabetes hospitalizations, shorter stays, and lower
Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.
In treated Cushing syndrome, normal late-night salivary cortisol was linked to better mood, quality of life, and metabolic outcomes, suggesting circadian cortisol restoration may be a meaningful recovery target.
Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Plasma profiling identified a three-miRNA panel associated with beta cell rate sensitivity across glucose tolerance stages, suggesting a minimally invasive approach to detect early insulin secretory decline.
A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula
In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.
Long-term follow-up after two lifestyle trials found that reductions in visceral fat, more than overall weight loss, were linked to sustained cardiometabolic benefits and a lower risk of type 2 diabetes.
REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.
In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, end
A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.
The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.
Open language-specific specialty feeds and department pages.